We compared the predictive value of SS with that of clinical parameters, including liver stiffness (LS), age, sex, body mass index, platelet count,

aspartate aminotransferase, alanine aminotransferase, bilirubin, albumin, prothrombin time, hyaluronic acid, and APRI. The presence of PSSs was evaluated using contrast-enhanced CT. [Results] The mean SS and LS were 2.58 and 1.46 Galunisertib cost m/s for patients with no varix (F0, n=58), 3.06 and 2.27 m/s for patients with grade 1 EVs (n=60), and 3.71 and 2.42 m/s for patients with grade 2 EVs (n=18), respectively. The SS of patients with EVs was significantly higher than that of patients without EVs (2.46 ± 0.45 vs.3.25 ± 0.48, P<0.001). The SS of patients with large varices was significantly higher than that of patients with small varices (2.69 ± 0.54 vs.3.58 ± 0.46, P<0.001). The area under the ROC for the prediction of the presence of a large varix (≥F2) by SS was 0.904; this value was the highest among the values of the other parameters (LS, 0.708; hyaluronic acid, 0.796; platelet count, 0.707; prothrombin time, 0.683; APRI, 0.662). When

SS and LS were evaluated with the presence of PSSs according to the esophageal grade, only SS in patients with F2 varices decreased with the presence of PSSs (3.78 and 3.34, P<0.012). However, these SS values were above the cutoff level of SS (2.87) for predicting varices. [Conclusion] SS could be a good predictor for EVs regardless of PSSs. Disclosures: Shuhei Nishiguchi - Consulting: Boehringer Ingelheim The following people have nothing to disclose: Hironori Tanaka, Hiroko lijima, Junko Nishimura, Chikage Nakano, Kenji Hashimoto, Temozolomide Noriko Ishii, Yukihisa Yuri, Īomoko Aoki, Kazunori Yoh, Akio Ishii, Tomoyuki Takashima, Yoshiyuki Sakai, Nobuhiro Aizawa, Kazunari Iwata, Naoto Ikeda, Yoshinori; Iwata, Hirayuki Enomoto, Masaki Saito Purpose. The

aim of this study was to compare dual cholate liver function MCE公司 testing to histologic stage of fibrosis in identifying those chronic HCV patients who have medium/large varices and those who are at risk for future clinical outcomes. Methods.221 chronic HCV patients enrolled in the HALT-C trial had dual cholate testing, liver biopsy, endoscopic screening for varices, and were followed for 4.9 ± 2.2 years for clinical outcomes. The patients had Ishak fibrosis scores of F2-6, CTP scores of 5 or 6, and no prior history of clinical complications. Oral choIate-2,2,4,4-d4 (40 mg) is taken up by enteric bile salt transporters directly into the portal vein and its clearance defined the Portal Hepatic Filtration Rate (HFR). IV choiate-24-13C (20mg) clearance defined the Systemic HFR. The ratio of Systemic to Portal HFR is the portal-systemic SHUNT. Archived serum was reanalyzed by an LCMS method validated to FDA guidelines for accuracy and precision. The Disease Severity Index (DSI)= 5.75(SHUNT) – 7.22(Log Portal HFR) – 8.45(Log Systemic HFR) + 50.